Vemurafenib Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 240 mg

Reference Brands: Zelboraf (USA/EU), Vemura (India)

Category: Oncology Cancer Care

Product Description:

Vemurafenib is a targeted anticancer medication used primarily for the treatment of metastatic or unresectable melanoma that carries a BRAF V600 mutation. It is a selective BRAF inhibitor that works by blocking the activity of the mutated BRAF V600E kinase, a protein involved in the MAPK signaling pathway that promotes tumor cell growth and proliferation. By inhibiting this pathway, vemurafenib helps slow down or stop the growth of cancer cells and supports better disease control in affected patients.

The drug has been approved for use in patients with BRAF-mutant melanoma and is also indicated for certain rare conditions such as Erdheim-Chester disease. In clinical practice, vemurafenib may sometimes be used in other cancers that carry BRAF mutations, including refractory non-small cell lung cancer and papillary thyroid cancer, when appropriate treatment options are limited. Clinical trials such as the BRIM studies demonstrated significant improvements in survival outcomes for patients with BRAF-mutant melanoma, which contributed to its regulatory approval.

While effective, treatment with vemurafenib may cause side effects such as skin reactions, rash, and increased sensitivity to sunlight. Because of potential risks, patients receiving this therapy require regular monitoring of liver, kidney, and heart function to ensure safe and effective treatment.